Search Results for: Mab

July 10, 2020July 10, 2020

Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19.

Publication date: Jul 08, 2020 Given its approval for the treatment of cytokine release syndrome, tocilizumab is under investigation in severe coronavirus disease-2019. To characterize serious adverse events (AEs) with ... Read more

July 10, 2020July 10, 2020

Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?

Coronavirus Literature

Publication date: Jul 07, 2020 Open Access PDF Concepts Keywords Infection Infection Tocilizumab Genentech Immunosuppressants Health care Semantics Type Source Name disease MESH infection drug DRUGBANK Tocilizumab disease MESH acute ... Read more

July 10, 2020July 10, 2020

Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19.

Coronavirus Literature

Publication date: Apr 27, 2020 Tocilizumab has been proposed as a means of opposing hyperinflammatory responses in intensive care patients with COVID-19. Here, we briefly discuss the potentially multiple, synergistic ... Read more

July 10, 2020July 10, 2020

Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.

Coronavirus Literature

Publication date: Jul 03, 2020 COVID-19, caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, in 2019 and has resulted in the current pandemic. The ... Read more

July 9, 2020July 9, 2020

Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases.

Coronavirus Literature

Publication date: Jun 17, 2020 Tocilizumab has been recognized as one of the few existing biologic useful for combating COVID-19 infections especially in critically ill patient. We had experience in ... Read more

July 8, 2020July 8, 2020

Tocilizumab in patients with severe COVID-19: A single-center observational analysis.

Coronavirus Literature

Publication date: Jun 17, 2020 Patients with coronavirus disease 2019 (COVID-19) may develop severe respiratory distress, thought to be mediated by cytokine release. Elevated proinflammatory markers have been associated with ... Read more

July 7, 2020July 7, 2020

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.

Coronavirus Literature

Publication date: Jul 03, 2020 To assess the safety and efficacy of interleukin (IL)-6 blockade with sarilumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation. We conducted an open-label ... Read more

July 7, 2020July 7, 2020

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Multiple Sclerosis News

Publication date: Jul 03, 2020 The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures ... Read more

July 5, 2020July 5, 2020

Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).

Coronavirus Literature

Publication date: Jun 30, 2020 There are limited data regarding treatment options for pregnant women with severe coronavirus disease 2019 (COVID-19). A 35-year-old primigravid patient at 22 weeks of gestation ... Read more

July 3, 2020July 3, 2020

Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B.

Melanoma Literature

Publication date: Jun 30, 2020 Combination therapy with reduced-dose programmed death 1 inhibitor plus standard-dose cytotoxic T-lymphocyte-associated antigen 4 inhibitor demonstrated efficacy, but substantial toxicity, in melanoma. We present long-term ... Read more